Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25925738 | 0.89 | OPRL1 (0.33) | OPRL1PDK1GBA1 | |
| SCHEMBL25925770 | 0.89 | OPRL1 (0.33) | OPRL1PDK1GBA1 | |
| SCHEMBL26406916 | 0.88 | OPRL1 (0.31) | OPRL1PDK1 | |
| SCHEMBL24764073 | 0.86 | PIK3CD (0.36) | PDK1 | |
| SCHEMBL25705576 | 0.86 | PIK3CD (0.36) | PDK1 | |
| SCHEMBL23696589 | 0.85 | OPRL1 (0.32) | OPRL1PDK1GBA1 | |
| SCHEMBL21107607 | 0.85 | OPRL1 (0.32) | OPRL1PDK1GBA1 | |
| SCHEMBL25478117 | 0.85 | OPRL1 (0.32) | OPRL1PDK1GBA1 | |
| SCHEMBL21106853 | 0.85 | OPRL1 (0.32) | OPRL1PDK1GBA1 | |
| SCHEMBL25478140 | 0.85 | OPRL1 (0.32) | OPRL1PDK1GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20210002296-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002296-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | OPRL1 4081/4885PDK1 1599/4885GBA1 2103/4885 |
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | OPRL1 2347/4885PDK1 504/4885GBA1 3212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.